OCTA1
Pre-clinical- Indications
- Bone fracture, Bone repair, Bone pain
Company intelligence / Profile preview
OsteoCure’s lead product—a multifunctional, injectable hydrogel—has demonstrated accelerated bone repair and reduced pain in healthy and impaired healing animal models. The technology leverages local delivery of naturally occurring small molecules like adenosine to promote osteogenesis, inhibit fat formation, increase angiogenesis, and provide analgesia. The company is advancing toward larger animal studies as a precursor to human clinical trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OsteoCure Therapeutics.